Introduction: Several maintenance therapies are available for treatment of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). The objective of this review was to assess the efficacy and safety of lenalidomide monotherapy in these patients.
Methods: MEDLINE, EMBASE, and the Cochrane Library databases were searched for publications up to April 7, 2021. Original studies that had information on lenalidomide monotherapy for DLBCL patients with R/R status were included. Meta-analyses of response rates, adverse events (AEs), overall survival (OS), and progression-free survival (PFS) were performed. The pooled event rates were calculated using a double arcsine transformation to stabilize the variances of the original proportions. Subgroup analysis was used to compare patients with different germinal center B-cell-like (GCB) phenotypes.
Results: We included 11 publications that examined DLBCL patients with R/R status. These studies were published from 2008 to 2020. The cumulative objective response rate (ORR) for lenalidomide monotherapy was 0.33 (95% CI: 0.26, 0.40), and the ORR was better in patients with the non-GCB phenotype (0.50; 95% CI: 0.26, 0.74) than the GCB phenotype (0.06; 95% CI: 0.03, 0.11). The major serious treatment-related AEs were neutropenia, thrombocytopenia, respiratory disorders, anemia, and diarrhea. The median PFS ranged from 2.6 to 34 months and the median OS ranged from 7.8 to 37 months.
Conclusion: This study provides evidence that lenalidomide monotherapy was active and tolerable in DLBCL patients with R/R status. Patients in the non-GCB subgroup had better responsiveness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674688 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.756728 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beyond HMAs: Novel Targets and Therapeutic Approaches.
Semin Hematol
December 2024
Department of Internal Medicine, Section of Hematology, Yale University and Yale Comprehensive Cancer Center, New Haven, Connecticut.
Article Synopsis
- * Treatment for lower-risk MDS focuses on improving quality of life and may include therapies like erythropoiesis-stimulating agents and new medications like imetelstat, while higher-risk MDS often utilizes hypomethylating agents as standard care, with ongoing research into combination therapies.
- * Despite advancements in treatment options, especially for higher-risk MDS, challenges remain due to limited effective therapies after initial treatment failures, highlighting the need for new drug developments that could change current treatment approaches.
[Current standard treatments and future outlook for follicular lymphoma].
Rinsho Ketsueki
October 2024
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research.
Article Synopsis
- * For patients with limited-stage FL, radiation therapy is preferred and can result in nearly 20 years of median survival, whereas advanced-stage patients with low tumor burden may benefit from a strategy of careful monitoring (watchful waiting).
- * Advanced-stage patients with high tumor burden typically receive chemoimmunotherapy, while various treatments are being explored for relapsed cases, including new therapies like CAR T-cell and bispecific antibodies.
Characterizing second line and beyond therapies for primary central nervous system lymphomas.
Hematol Oncol
November 2024
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
- Primary central nervous system lymphoma (PCNSL) is a rare and aggressive cancer affecting the brain and spinal cord, typically treated with high-dose methotrexate (HDMTX) combined with other therapies, but many patients relapse after initial treatment.
- A study analyzed 54 adult PCNSL patients who received HDMTX-based treatment from 2016 to 2022, revealing that 57% underwent consolidation therapy, while 24% had autologous stem cell transplants.
- For those with relapsed or refractory (R/R) disease, treatments varied widely, including second and third line options like whole brain radiation (WBRT), clinical trials, and various combinations of rit
Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determination in plasma.
Cancer Chemother Pharmacol
November 2024
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.
Ruxolitinib (RUX), a Janus kinase 2 (JAK2) inhibitor, and lenalidomide (LEN), an immunomodulatory agent, have recently been proposed as a combined treatment for myelofibrosis (MF). This combination has demonstrated improved efficacy, safety, and tolerability compared to monotherapy. To further refine these findings, an efficient analytical tool is needed to simultaneously determine RUX and LEN concentrations in blood plasma.
View Article and Find Full Text PDFArticle Synopsis
- This study aimed to assess the effectiveness of epcoritamab, a new bispecific antibody, for treating patients with advanced follicular lymphoma who have already undergone multiple previous therapies.
- The research was part of the EPCORE NHL-1 trial, which took place at 88 sites across 15 countries and involved patients aged 18 and older with specific eligibility criteria, including having received at least two prior treatments.
- Treatment involved subcutaneous injections of epcoritamab in cycles, with a tailored dosing strategy to minimize the risk of cytokine release syndrome, and the primary focus was on evaluating the overall response rate and safety measures related to cytokine release.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!